List of works - Tomasz Stokłosa

A rare mutation in a rare tumor-SMARCB1-deficient malignant glomus tumor

A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index

scientific article published on 01 September 2002

A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations

scientific article published on 3 April 2015

ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques

scientific article published on 5 March 2013

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks

scientific article

Angiotensin I-converting enzyme and chymase gene polymorphisms - relationship to left ventricular mass in type 2 diabetes patients

scientific article published in August 2002

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice

scientific article published on 22 April 2013

Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice

scientific article published on 01 October 1997

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

scientific article

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations

scientific article

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

scientific article published on 9 March 2006

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

scientific article published on 10 August 2004

BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance

scientific article

BRAF--a new player in hematological neoplasms

scientific article published on 02 February 2014

Bright, color-tunable fluorescent dyes based on π-expanded diketopyrrolopyrroles

scientific article published on 14 May 2012

Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line

scientific article published on November 2001

Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin.

scientific article published on January 2008

Correction to Bright, Color-Tunable Fluorescent Dyes Based on π-Expanded Diketopyrrolopyrroles

scientific article published on 02 January 2015

DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease

scientific article published on 07 February 2018

Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia-From Single Cell Analysis to Next-Generation Sequencing

scientific article published on 29 September 2020

Differential expression of BIRC family genes in chronic myeloid leukaemia--BIRC3 and BIRC8 as potential new candidates to identify disease progression

scientific article published on 25 November 2013

Direct tumor damage mechanisms of photodynamic therapy.

scientific article

Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia

scientific article published on 5 February 2013

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells

scientific article

Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

scientific article published on December 2007

G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice

scientific article published on 01 January 1998

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

scientific article published on 8 May 2017

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

scientific article published on 29 March 2013

Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics

Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm

scientific article published on 11 April 2019

Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity.

scientific article

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

scientific article published on 21 June 2011

Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.

scientific article published in May 2005

Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor.

scientific article published in March 2004

Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice

scientific article published on 01 February 2000

Lovastatin and simvastatin are modulators of the proteasome.

scientific article

Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.

scientific article

Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.

scientific article published on 15 October 2016

Next Generation Sequencing in Oncology

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

scientific article published on 10 February 2016

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells

scientific article published on 8 January 2016

Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.

scientific article published on June 2007

Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo

scientific article published in April 2001

Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib

scientific article published on 15 November 2020

Prospects for p53-based cancer therapy.

scientific article

Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response

scientific article published on 12 May 2009

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

scientific article

Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome

scientific article

Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net

scientific article published in January 2010

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

scientific article

Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib

scientific article published on 22 March 2014

Synthesis and Optical Properties of Tetraaryl-1,4-dihydropyrrolo[3,2-b]pyrroles

Technology evaluation: SB-485232, GlaxoSmithKline.

scientific article

Terapia przewlekłej białaczki szpikowej – teraźniejszość i wyzwania na przyszłość

The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells

scientific article

The influence of photodynamic therapy on the immune response.

scientific article

The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production

scientific article published on 01 December 1999

Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations

scientific article

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

scientific article

Whole-exome sequencing in patients with protein aggregate myopathies reveals causative mutations associated with novel atypical phenotypes

scientific article published on 10 November 2020

Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice

scientific article

List of works by Tomasz Stokłosa

A rare mutation in a rare tumor-SMARCB1-deficient malignant glomus tumor

A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index

A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations

ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks

Angiotensin I-converting enzyme and chymase gene polymorphisms - relationship to left ventricular mass in type 2 diabetes patients

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice

Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance

BRAF--a new player in hematological neoplasms

Bright, color-tunable fluorescent dyes based on π-expanded diketopyrrolopyrroles

Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line

Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin.

Correction to Bright, Color-Tunable Fluorescent Dyes Based on π-Expanded Diketopyrrolopyrroles

DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease

Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia-From Single Cell Analysis to Next-Generation Sequencing

Differential expression of BIRC family genes in chronic myeloid leukaemia--BIRC3 and BIRC8 as potential new candidates to identify disease progression

Direct tumor damage mechanisms of photodynamic therapy.

Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells

Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells

G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics

Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm

Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity.

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.

Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor.

Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice

Lovastatin and simvastatin are modulators of the proteasome.

Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.

Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.

Next Generation Sequencing in Oncology

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells

Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.

Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo

Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib

Prospects for p53-based cancer therapy.

Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/beta-lactone is not a specific inhibitor of the proteasome

Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib

Synthesis and Optical Properties of Tetraaryl-1,4-dihydropyrrolo[3,2-b]pyrroles

Technology evaluation: SB-485232, GlaxoSmithKline.

Terapia przewlekłej białaczki szpikowej – teraźniejszość i wyzwania na przyszłość

The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells

The influence of photodynamic therapy on the immune response.

The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production

Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Whole-exome sequencing in patients with protein aggregate myopathies reveals causative mutations associated with novel atypical phenotypes

Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice